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Introduction 
T. E. Starzl 
Transplantation Institute. 3601 Fifth Avenue. Pittsburgh PA 152 J 3. USA 
H etero transplantation, or xenotransplantation, is no exception to the axiom that history repeats itself. The first attempts at whole organ transplantation were made between 1906 and 1923 
using pig, sheep, goat, and subhuman primate kidney donors, and are summarized by Groth(3). 
The first of these efforts were in France and Germany, and in some the blood vessels coming to and 
leaving these organs were sewn to recipient blood vessels in much the same way as today(8.22l. None 
of the kidneys functioned for long, if at all, and the human recipients died from a few hours to 9 days 
later. 
No further trials were made until the surge of enthusiasm caused in 1963 by the repeated success of 
renal allotransplantation (using predominantly living related donors) with combined azathioprine-
prednisone therapy' 18). Brain death as a condition for cadaveric donation was 5 years in the future, 
the supply of living donors was limited, and desperate potential kidney recipients were piling up faster 
than places could be found for them in the few existing dialysis programmes. 
At the height of the crisis, heterotransplantation was re-explored. On 16 February 1963. Claude 
Hitchcock of Hennepin County Hospital, Minneapolis. transplanted the kidney of a baboon into a 
65-year-old woman. The organ functioned for 4 days before its artery clotted,6'. The case was not 
made public until it was learnt. later in the same year, of a far more encouraging experience by Keith 
Reemtsma of Tulane University using the closer-to-human chimpanzee donor' 14'. One of Reemstma' s 
chimpanzee kidney grafts functioned for 9 months. Reemstma also transplanted a rhesus monkey 
kidney which was fiercely rejected. 
Subsequently, Cortesinier (//.'~'. and probably others who did not report their cases. accumulated 
chimpanzee heterotransplantation experience. generally confirmatory of Reemstma·s. and Hardy 
attempted a chimpanzee-to-human heart transplant which failed peri-operatively's,. Liver heterotrans-
plantation with chimpanzee donors was attempted three times by us, 19 or more years ago. with 
maximum survival of I) days. summarized in llSI . The histopathological findings at autopsy were not 
distinguishable from those in allografts at comparable times. No further attempts have been made 
using modern immunosuppression (with cyclosporine I. and are not likely to be. because of the 
endangered status of chimpanzees and their increasingly recognized humanoid qualities l41 . 
Much is also known about baboon to human transplantation. In December 1963 and January 106-+. 
six patients were given baboon kidneys at the University of Coloradotl71 . All the organs functioned 
promptly and maintained their function for 10 to 60 days. However. the necessary doses of azathio-
prine and prednisone were very high. and eventually the grafts were rejected. The n:Jecl1on was 
midway 111 severity between that 01 the chimpanzee and rhesus kidneys but not qualitativcly different 
from that observed in some homografts in which there was a humoral component' I' '. The same events 
were recapitulated two decades later III the Baby Fae baboon-tn-human heart transplant in spite ot 
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heavy cyclosporine-steroid immunosuppression!)). It was clear that the use of baboon organs would 
have to wait for better and possibly fundamentally different immunosuppression. assuming that 
baboons, more plentiful and with a seemingly more distant anthropomorphic separation, might be a 
socially and ethically acceptable donor. This latter issue is certain to be hotly debated even if clinical 
trials are successful. 
All of the baboon kidneys (and Baby Fae's heart) developed spotty necrosis or uneven regional 
infarctions. It was unfortunate that there were not better humoral antibody studies in these early days. 
The technology for this was not then developed and Iymphocytotmdc antibodies as a cause for 
humoral allograft rejection were not recognized until 1964(21). However. even in early 1963. we 
measured heterospecific antibodies that mayor may not have been relevant to the eventual destruction 
of the baboon kidneys. It was evident from declines in their titres and confirmatory electron 
micrographic studies that heteroagglutinins bound to the grafts( 17). K.A. Porter, the London patholog-
ist who was working with us. concluded: 'In the resulting rejection process, cellular infiltration and 
peritubular capillary destruction are prominent early pathologic features, but in nine days the 
vasculonecrotic element is marked. There is circumstantial evidence to suggest that, whereas the 
peritubular capillary damage is mediated by cell-bound antibody, the fibrinoid necrotic vascular 
lesions are caused by circulating antibodies:!I3). 
The serological and histopathological indictment of antibodies was prophetic. The humoral compo-
nent of rejection has been the central topic for any discussion of transplantation between species since 
that time' )9). In fact. xenograft models have been used to evaluate treatment of hyperacute rejection 
of allografts in sensitized recipients with the assumption that the mechanisms of destruction of 
xenografts is by the same process. Such techniques to prevent humoral rejection have been sum-
marized elsewhere!l9) (see also Part II) and include plasmapheresis. antibody removal with a Staph 
A column to reduce the antibody titre; infusion of citrate. a chelating agent and anticoagulant - which 
is also very efficient in preventing complement activation - and the use of prostanoids and other 
inhibitors of the intlammatory response. Of these approaches. it is curious that the most promising. 
i.e. prostaglandin (PG) therapy has received the least attention. PGE) can unequivocally mitigate the 
xenograft rejection of cat to dog())). hamster to rat! 9) and pig to dog! 10l. [n FK-S06-based drug 
cocktails. PGE I • in combination with steroids, converts the prognosis oflymphocyroroxic crossmatch-
positive liver allograft recipients to the same as those given crossmatch-negative organs!1OJ. 
Generally speaking. the humoral antibody barrier becomes more extreme. roughly in proportion to 
the degree of species disparity. so that with widely divergent species. humoral rejection usually occurs 
within a few minutes. However. trial and error has been the only way to rise above speculation with 
any given animal to human combination. Thus. dwelling on the historical experience with clinical 
heterotransplantation reflects more than an idle preoccupation. Each of these transplant efforts has 
yielded information about the extent of the human barrier to the particular species used. 
Success was tantalizingly close with the chimpanzee. baboon. and rhesus monkey. in that order. 
Because the pig is often mentioned as a possible clinical organ donor. it is important to recount an 
unreported attempt by Rene Kuss. the pioneer French transplant surgeon. at a pig-to-human renal 
transplant in the early I 960s under azathioprine and prednisone (personal conversation in November 
1990 with Rene Kuss and Jacques Poisson). The kidney functioned well for approximately 30 min 
hut then underwent hyperacute rejection. The dominant finding was widespread thrombosis of the 
microvasculature. concentrated in the venuks. Kuss' willingness to share (his experience almost three 
decades later was important because it would be difficult. in the climate of today. to acquire (his kind 
nf vitally needed information. The pig will not be easy. 
Those who were driven hy an organ shortage in the early 1960s to attempt renal heterotransplantation 
found an abandoned camp fire left by workers at the turn of the century. and in !Urn were forced 
themselves to give up their bivouac. Now the cycle has begun again with the stimulus of an impending 
or actual shortage or organs for transplant procedures (kidney. liver and heart) which if successful 






PART XIV - IfIlrnduction 
This time, the tools of cellular immunology and molecular biology are sophisticated beyond the 
comprehension of most practising physicians and surgeons. Yet, serious gaps at a less esoteric level 
still exist. It is conceded that the antibody barrier is the presently insurmountable obstacle, but what 
to do about it, or even if the critical antibodies are of the IgM or IgG class, are debated constantly. 
Strategies are focused on the prevention of endothelial cell activation of the vasculature of solid 
organs, possibly with gene transfection or by inhibiting complement components(l2), or by creation 
of xenogeneic chimeras with contemporaneous or prior bone marrow transplantation(7). 
In spite of optimistic speculation, the related but easier problem has eluded solution of surmounting 
the lymphocytotoxic allospecific antibodies which prevent the transplantation of a growing popula-
tion of potential renal recipients. If humoral rejection of allografts, and then of xenografts, could be 
prevented there is much speculation, and some evidence, that subsequent cellular immunity will be 
less formidable with xenografts than with allografts(l2). 
However, support for this idea has come only from in vitro experiments and has engendered instinctive 
scepticism. Nature is not usually this careless. 
If heterotransplantation can be accomplished. it is almost certain that the difficulty will vary with 
different organs. Because it is resistant to antibody-mediated rejection(l9), the liver is expected to be 
at the easy end of the spectrum. However, success could carry its own new set of penalties. Many 
genetic disorders are caused and defined by specific defects of the body's chemical machinery. If 
these are liver based. they are corrected by liver transplantation because the hepatocytes retain the 
metabolic specificity of the donor even though the lymphoreticular cells are repopulated by cells of 
the recipient( In). It is conceivable that iatrogenic inborn errors of metabolism could be caused by the 
proteins and other synthetic products of the heterograft liver in proportion to the species disparity 
between the animal donor and the human recipient. 
No matter what the organ, those who have worked with heterografts in the laboratory or clinic have 
the kind of respect for the species barrier that has been nourished by the frustration of repeated failures. 
The techniques of immunosuppression which already have brought organ allotransplantation to a high 
level of success will be part of the therapy required, but something else which is not yet apparent will 
be needed. The artful manipulation orthe immune system to achieve tolerance has not been practical 
even for allotransplantation. and it is difficult to imagine that this approach will allow the widespread 
use of animal organs. I believe that the answer will be in drugs which inhibit other targets than those 
of classical immunosuppression. The most successful agents for antibody rejection are apt to be those 
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